Mr. Alvaro Torres reports

KHIRON SUCCESSFULLY COMPLETES FIRST MEDICAL CANNABIS SALE IN BRAZIL

Khiron Life Sciences Corp. has successfully completed its first sale of medical cannabis product in Brazil. Leveraging production, distribution, and clinical assets in Latin America, along with marketing agreements with leading pharmaceutical distributors, Khiron plans to expand its presence in Brazil, a market of over 200 million people.

"Our initial export to the Brazilian market represents an important first step toward opening a large, underserved market where patients face high barriers to access. By providing patients with affordable high-quality products, and an unparalleled patient experience, we see an opportunity to disrupt the Brazilian market and deliver on our mission of improving patients lives. Khiron is already treating thousands of patients in Colombia, Peru, U.K. and Germany, with positive outcomes. In due course, we plan to bring our successful Zerenia clinic model to Brazil, as we have done in Peru and Colombia," comments Alvaro Torres, chief executive officer and director.

Through the company's strategic alliance with Cannab, a patient association that connects physicians, patients, academic institutions and suppliers, a three-year-old child from Salvador de Bahia suffering from epilepsy has received six units of Khiron high-CBD (cannabidiol) 100 milligram per 50 millilitre extract. The importation of Khiron's medical cannabis on behalf of the patient was authorized by ANvisa (the Brazilian National Health Surveillance Agency). The company plans to collaborate with Cannab to continue offering its medical products to many more patients. Cannab expects to help over 1,200 new patients gain access to medical cannabis products during 2021. According to Prohibition Partners, the Brazilian medical cannabis user base could reach close to three million people in the next few years.

The company has also established two partnerships in Brazil to increase product awareness and medical cannabis education for health care providers across the country. As previously announced, Khiron has an exclusive agreement with Medlive, a pharmaceutical and health products distributor with a network of over 3,000 clinics and hospitals in southern Brazil. In addition, the company has signed a marketing contract with Taimin, a leading medical distributor focused on Rio de Janeiro, Sao Paulo and northern Brazil. Together, the two agreements provide broad regional coverage across Brazil and are intended to drive sales by expanding Khiron's network of prescribing physicians. The company is also in discussion with several medical clinics as it seeks to expand its clinic model into Brazil.

About Khiron Life Sciences Corp.

Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The company has a sales presence in Colombia, Peru, Brazil, Germany and the United Kingdom, and is positioned to commence sales in Mexico in 2021. The company is led by co-founder and chief executive officer, Mr. Torres, together with an experienced and diverse executive team and board of directors.

We seek Safe Harbor.